PRP treatment
Phase 2Biologic
PRP treatment is one of 84 biologic programs targeting Low back pain. It is currently in Phase 2.
2
Indications
2
Total Trials
1
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
143 competitors in Osteoarthritis
#DrugCompanyPhaseTrials
1Toradol
RochePreclinical
Cataflam
NovartisPreclinical
Bayer Aspirin
BayerPreclinical
Enbrel
IImmunex
Preclinical
PRP treatment
RRegenexx, LLC
Phase 2
Glucophage
EMD SeronoPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Protonix
WWyeth-Lederle Vaccines
Preclinical
Catapres
Boehringer IngelheimPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PRP treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- RRegenexx, LLC